|
AU2012261545A1
|
|
Immunogenic compositions for Chlamydia trachomatis
|
|
AU2012209025A1
|
|
Imidazoquinoline compounds
|
|
AU2007231677A1
|
|
Adjuvanted meningococcus compositions
|
|
AU2007214362A1
|
|
KGF polypeptide compositions
|
|
AU2007203399A1
|
|
TTK in diagnosis and as a therapeutic target in cancer
|
|
AU2007202500A1
|
|
Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
|
|
AU2007238636A1
|
|
Methods of treating, diagnosing or detecting cancer
|
|
AU2006335256A1
|
|
Norovirus and sapovirus antigens
|
|
AU2006235276A1
|
|
CACNA1E in cancer diagnosis, detection and treatment
|
|
AU2006200923A1
|
|
Methods for pulmonary delivery of interleukin-2
|
|
AU2005202068A1
|
|
Quinolinone derivatives as tyrosine kinase inhibitors
|
|
AU2005241107A1
|
|
Crystalline forms of 9-(S)-erythromycylamine
|
|
AU2005227263A1
|
|
In vitro test system for predicting patient tolerability of therapeutic agents
|
|
AU2005216904A1
|
|
Modulation of inflammatory and metastatic processes
|
|
AU2005206570A1
|
|
Tetrahydrocarboline compounds as anticancer agents
|
|
AU2005200246A1
|
|
Neisseria genomic sequences and methods of their use
|
|
AU2004305111A1
|
|
Cell transfecting formulations of small interfering RNA, related compositions and methods of making and use
|
|
ME01876B
|
|
Use of antagonistic anti-cd40 monoclonal antibodies
|
|
AU2004287480A1
|
|
Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia
|
|
EP1626708A2
|
|
Immunogenic reagents from west nile virus
|
